{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pfizer+COVID-19+mRNA+vaccine&page=2",
    "query": {
      "intervention": "Pfizer COVID-19 mRNA vaccine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pfizer+COVID-19+mRNA+vaccine&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pfizer+COVID-19+mRNA+vaccine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T00:45:58.405Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06038617",
      "title": "Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fever After Vaccination",
        "Fever",
        "Seizures Fever"
      ],
      "interventions": [
        {
          "name": "mRNA COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Routine Childhood Vaccinations",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "4 Years",
        "sex": "ALL",
        "summary": "6 Months to 4 Years"
      },
      "enrollment_count": 347,
      "start_date": "2023-10-30",
      "completion_date": "2025-07-25",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-10-07T00:45:58.405Z",
      "location_count": 5,
      "location_summary": "Oakland, California • Atlanta, Georgia • New York, New York + 2 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06038617"
    },
    {
      "nct_id": "NCT05212610",
      "title": "Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COVID-19",
        "Corona Virus Infection"
      ],
      "interventions": [
        {
          "name": "Pfizer-BioNTech mRNA COVID-19 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Moderna mRNA COVID-19 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 137,
      "start_date": "2022-03-21",
      "completion_date": "2025-03-07",
      "has_results": true,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-07T00:45:58.405Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05212610"
    },
    {
      "nct_id": "NCT04977479",
      "title": "The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Allergic Reaction"
      ],
      "interventions": [
        {
          "name": "Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Pfizer-BioNTech COVID-19 Vaccine, Bivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "16 Years to 69 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-09-08",
      "completion_date": "2023-02-22",
      "has_results": true,
      "last_update_posted_date": "2023-10-16",
      "last_synced_at": "2026-10-07T00:45:58.405Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04977479"
    },
    {
      "nct_id": "NCT04954287",
      "title": "Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "CVXGA1 low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CVXGA1 high dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CyanVac LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2021-08-06",
      "completion_date": "2023-06-10",
      "has_results": false,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-10-07T00:45:58.405Z",
      "location_count": 4,
      "location_summary": "Bardstown, Kentucky • Rochester, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Plano",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04954287"
    },
    {
      "nct_id": "NCT04843774",
      "title": "Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "SARS-COV-2 mRNA Vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2021-04-20",
      "completion_date": "2023-04-18",
      "has_results": false,
      "last_update_posted_date": "2023-11-08",
      "last_synced_at": "2026-10-07T00:45:58.405Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • New York, New York",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04843774"
    },
    {
      "nct_id": "NCT04761822",
      "title": "COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV Infection",
        "COVID-19",
        "Allergic Reaction",
        "Mast Cell Disorder"
      ],
      "interventions": [
        {
          "name": "Moderna COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pfizer-BioNTech COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 746,
      "start_date": "2021-04-07",
      "completion_date": "2022-04-27",
      "has_results": true,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-07T00:45:58.405Z",
      "location_count": 29,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04761822"
    },
    {
      "nct_id": "NCT04848584",
      "title": "Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 BA.4/5 bivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "XBB.1.5-adapted vaccinated",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-05-15",
      "completion_date": "2025-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-10-07T00:45:58.405Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04848584"
    },
    {
      "nct_id": "NCT04878211",
      "title": "A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis (RMS)"
      ],
      "interventions": [
        {
          "name": "Ofatumumab",
          "type": "DRUG"
        },
        {
          "name": "mRNA COVID-19 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "interferon or glatiramer acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-06-10",
      "completion_date": "2023-04-14",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-10-07T00:45:58.405Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Hollywood, Florida • Wellesley, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Wellesley",
          "state": "Massachusetts"
        },
        {
          "city": "Plymouth",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04878211"
    },
    {
      "nct_id": "NCT05020145",
      "title": "COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immunocompromised",
        "Immunosuppressed",
        "Covid-19",
        "SARS-COV-2",
        "SARS-COV-2 Infection",
        "Breakthrough Infection"
      ],
      "interventions": [
        {
          "name": "BNT162b2 (Tozinameran)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1277747,
      "start_date": "2021-08-25",
      "completion_date": "2021-12-17",
      "has_results": true,
      "last_update_posted_date": "2024-02-12",
      "last_synced_at": "2026-10-07T00:45:58.405Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05020145"
    },
    {
      "nct_id": "NCT07390968",
      "title": "Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphatic System Neoplasm"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 mRNA Vaccine ARCT-021",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tozinameran",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2026-12-01",
      "completion_date": "2029-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-07T00:45:58.405Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07390968"
    }
  ]
}